NASDAQ$SRTA
Strata Critical Medical Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Announced second quarter 2024 results with improved net loss and positive Adjusted EBITDA.
Blade Air Mobility reported an 11.4% increase in total revenue to $67.9 million, marking its first Adjusted EBITDA positive Q2 as a public company. The Medical and Passenger segments demonstrated strong performance, contributing positive Segment Adjusted EBITDA. The company is reaffirming its guidance for full year 2024, expecting revenue of $240 million to $250 million and positive Adjusted EBITDA.
- Net loss improved by $0.9 million versus the prior year to $(11.3) million in Q2 2024
- Adjusted EBITDA improved by $5.4 million versus the prior year to $1.0 million in Q2 2024
- Medical revenue reached $38.3 million in Q2 2024, a 6.4% sequential increase versus Q1 2024
- Passenger Segment Adjusted EBITDA was positive, improved by $2.9 million versus the prior year period
Headline financials
Revenue & EPS history
Strata Critical Medical · Revenue · Quarterly
$67.9M
Forward guidance
The Company is reaffirming its guidance. For the full year 2024, we expect Revenue of $240 million to $250 million and Positive Adjusted EBITDA. For the full year 2025, we expect Double-digit year-over-year revenue growth and Double-digit Adjusted EBITDA
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+3.4%
Avg return
Earnings day
+2.8%
Avg return
5 days after
+5.7%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+38.8%
Q3 2023
Best reaction
-32.1%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.6% | +17.2% | +19.7% | |
| Q4 2025 | +6.9% | +1.1% | -7.6% | |
| Q3 2025 | +9.5% | +8.1% | +4.3% | |
| Q1 2025 | +18.7% | +20.5% | +41.4% | |
| Q4 2024 | +7.1% | +8.1% | -4.9% | |
| Q3 2024 | -4.4% | -17.5% | +8.9% | |
| Q2 2024 | +17.3% | +3.6% | +2.9% | |
| Q1 2024 | -3.3% | -3.3% | -16.0% | |
| Q4 2023 | -32.1% | -32.3% | -3.5% | |
| Q3 2023 | +38.8% | +44.5% | +44.5% | |
| Q2 2023 | -7.9% | -6.7% | -24.3% | |
| Q1 2023 | +9.4% | +2.8% | +28.1% | |
| Q4 2022 | -9.7% | -22.3% | -32.0% | |
| Q3 2022 | -2.3% | -0.2% | +3.4% | |
| Q2 2022 | +8.0% | +6.9% | -17.5% | |
| Q1 2022 | -15.0% | +0.9% | -2.3% | |
| Q4 2021 | -3.2% | +5.2% | -2.0% | |
| Q3 2021 | +0.3% | +2.1% | +41.4% | |
| Q2 2021 | +18.0% | +16.4% | +58.7% | |
| Q1 2021 | +13.7% | +11.8% | -11.8% | |
| Q4 2020 | -0.1% | -0.1% | +3.1% | |
| Q2 2020 | +0.0% | -0.2% | -0.1% | |
| Q1 2020 | +1.0% | +1.0% | +1.3% | |
| Q4 2019 | -0.2% | -0.3% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro